Todd Sone
Todd Sone has over fifteen years of healthcare and finance experience. Todd is a Venture Partner at Signet and has served on the Board of Arbor Pharmaceuticals and Apicore.
Prior to joining Signet, Todd was an Investment Director at Joddes Limited, an investment holding company with interests in a number of healthcare companies, including Pharmascience, Paladin Labs, Medicom, and Oral Science. He was the Director of Strategic Planning at Pharmascience Inc., one of the largest privately-owned generic pharmaceutical companies in the world.
Prior to joining Pharmascience, Todd was a large-cap pharmaceutical analyst at Morgan Stanley. He started his career at Mercer Management Consulting serving clients across North America in the transportation and healthcare industries.
Todd received a Bachelor of Commerce (with High Distinction) from the University of Toronto and an MBA from The Wharton School at the University of Pennsylvania.
David Tierney, MD
David Tierney, MD is a Venture Partner with Signet Healthcare Partners. He serves as an advisor to Signet and also works closely with Signet portfolio companies. David currently serves as the CEO of Icon Bioscience.
Previously, David served as President & COO of Oceana Therapeutics, Inc., a specialty therapeutic company he co-founded in mid-2008. Oceana quickly established a global commercial network and by December 2011 was acquired by Salix Pharmaceuticals. In 2000, David was appointed President & CEO of Hydro Med Sciences (HMS), a research firm with a promising drug delivery platform. Under his leadership, HMS emerged as Valera Pharmaceuticals, a fully integrated, commercial, specialty pharma company that successfully completed an initial public offering in 2005. Valera has since been merged into Endo Pharmaceuticals. Prior to Valera, David was President of Biovail Technologies, a drug delivery division of Biovail Corporation – a predecessor to Valeant Pharmaceuticals International. Earlier in his career, he served as Senior VP, Drug Development at Roberts Pharmaceutical and in a variety of management positions at Elan Corporation.
David serves on the Board of Catalyst Pharmaceuticals, Inc (NSDQ: CPRX), Kempharm, Inc (NSDQ: KMPH) and Viatar CTC Solutions.
David received his medical degree from the Royal College of Surgeons in Dublin, Ireland.
Joyce Erony
Joyce Erony has more than 25 years of experience as a principal in investing activities, investment banking and business development. Joyce is a Partner Emeritus at Signet and serves as a Director of ImpoPharma, Icon Biosciences and Kew Group.
Joyce was previously a Director of IGI Labs, Peak Surgical (acquired by Medtronic), Dow Pharmaceutical Sciences (acquired by Valeant), Anteis (acquired by Merz), Atlantis Components (acquired by AstraZeneca), and Control Delivery Systems (acquired by Psivida).
Previously, Joyce was a strategic advisor to Alcon Labs and a Managing Director at Citigroup where she was focused on specialty pharmaceuticals and medical technologies.
Martin Zeiger
Martin (Marty) Zeiger has more than 30 years of experience in the pharmaceutical industry, both branded and generic. Martin is an Adjunct Partner at Signet and is a Director of Sancilio & Company.
Prior to joining Signet Healthcare Partners, Martin was a Senior Vice President at Barr Laboratories, Inc. Prior to joining Barr, Martin was Executive Vice President and General Counsel at Rugby Laboratories (a privately held generic drug company) until its acquisition by Marion Merrill Dow, Inc. in 1993. He continued as a Vice President for Marion and its successor Company, Hoechst Marion Roussel, Inc.
Martin was honored by the Generic Pharmaceutical Industry Association at its March 2004 Annual Meeting as a generic industry founder. Prior to joining pharmaceutical manufacturing companies, Martin served as Vice President General Counsel for Jack Eckerd Corporation and Senior Vice President for Revco D.S. Inc., both major drug store retailers.
Martin received his LLB and JD from St. John’s University School of Law, where he served as Publications Editor of the Law Review. He is an attorney, admitted to practice in the State of New York.